Our Treatments
Saisei GcMAF is produced using a Patented process which was developed here in Japan by
Saisei Mirai in collaboration with researchers from the University of Tokushima who have been studying GcMAF for over 20 years!
P53 and PTEN Cancer Gene Therapy
Cancer gene therapy using normal P53 and PTEN tumor suppressor genes
Sonodynamic Therapy (SDT)
Sonodynamic therapy (SDT) is a non-invasive cancer treatment that uses ultrasound and a chemical agent to treat tumors
Tumor Treating Field (TTF)
TTF therapy is a type of electric fields therapy using low-intensity electric fields to suppress cancer cell proliferation in the body.
High-Intensity Focused Ultrasound (HIFU)
An advanced treatment method that focuses ultrasound energy on a target area to induce tissue necrosis through the effects of thermal energy and cavitation.
Our Recent Articles
Oral intake of degalactosylated
whey protein increases peripheral
blood telomere length in young
and aged mice
The Effects of Dietary Intervention and Macrophage-Activating
Factor Supplementation on Cognitive Function in Elderly Users of Outpatient Rehabilitation
Degalactosylated Whey Protein Suppresses Inflammatory Responses Induced by Lipopolysaccharide in Mice
The Effect of MAF Capsules and M Capsules on Lymphopenia and Clinical Outcomes in Non-Critical Hospitalized COVID-19 Patients
Adjunctive use of oral MAF is associated with no disease progression or mortality in hospitalized patients with COVID-19 pneumonia: The single-arm COral-MAF1 prospective trial (Italy)
News
Saisei Medical Conference 2024 – Highlights from Osaka
On October 20, 2024, we hosted the Saisei Medical Conference in Osaka, featuring expert speakers from Indonesia, Singapore, India, Canada, and beyond. The event covered key topics like immunity support, longevity, thyroid function, and the potential of Klotho gene overexpression in aging.
We are grateful to all the speakers and attendees for their contributions, making this a successful event that fostered valuable global collaboration in healthcare and medical research.
Please register here to watch the recording of the conference
Dr Inui and Dr Kubo took part in the Indonesian Integrative conference, held in Jakarta, on August 25, 2024, where they gave a presentation on GcMAF, Cancer treatments in Saisei Mirai and Sono Dynamic Therapy
This time, the Saisei Mirai, has contracted official partnership with the Ukrainian National Cancer Center as partner hospitals.
Autism spectrum disorder (ASD)
What are the main factors of ASD? How is ASD connected with microglia? Learn more about ASD improvement methods at Saisei.
Cancer
Is it possible to defeat cancer? Learn about cutting-edge technologies at Saisei to help your immune system fight cancer.
Saisei Clinics
Saisei Clinics is a pioneering medical clinic that leverages innovative technologies and the latest advancements in medicine through collaborations with leading Japanese and international research institutes and companies. We proudly hold patents for several unique technologies and products designed to enhance natural immunity and rejuvenate the entire body at the cellular level.
While we acknowledge traditional methods of treatment, our primary goal is to assist patients in overcoming various disorders and dysfunctions by harnessing their innate immunity and promoting internal rejuvenation. We focus on normalizing the natural vital immunity of individuals. In addition to immunotherapy, our clinic has developed a cutting-edge form of gene therapy known as liposomal gene therapy, recognized for its exceptional effectiveness and safety.
At our clinic, each patients are highly valued, and we tailor our approach to provide an individualized combination of treatment methods based on their medical history, predispositions, and current condition. Our guiding principle is “FIRST DO NO HARM.” Our treatments are grounded in scientific research, ensuring safety and minimal side effects. Even if patients are undergoing traditional medical treatments, they can confidently incorporate our methods as complementary therapies.
For more information about our treatment methods, please scroll below.
At our clinic, each patients are highly valued, and we tailor our approach to provide an individualized combination of treatment methods based on their medical history, predispositions, and current condition. Our guiding principle is “FIRST DO NO HARM.” Our treatments are grounded in scientific research, ensuring safety and minimal side effects. Even if patients are undergoing traditional medical treatments, they can confidently incorporate our methods as complementary therapies.
For more information about our treatment methods, please scroll below.
Our Team
Dr. Toshio Inui
CEO of Saisei Mirai Clinic group
Dr. Kentaro Kubo
Director Saisei Mirai Cell Processing Center (CPC)
Dr. Kiyo Fujita
Saisei Serbia
Dr. Galyna Kutsyna
Saisei Ukraine
Our Clinics in Japan
We have 3 clinics in Japan: Tokyo, Osaka and Kobe.
Keihan Clinic, Osaka
Saisei Mirai Clinic, Kobe
Science Clinic, Tokyo
Cell Processing Center
Our Clinic Abroad
Saisei Serbia
We are pleased to announce the opening of our clinic in Serbia. For additional information and inquiries, please feel free to contact us using the details below.
- Tel: +381 11 6707 180
- Tel: +381 66 803 5888
- Address: Borisavljevicevay 29, Beograd 11000, Serbia
- Web: https://saiseiserbia.com/
Saisei Group
Saisei Spain
Saisei Sweden
Saisei Moscow
Temporarily closed
Saisei Ukraine
Temporarily closed
Saisei Pharma is a bio venture company established at Tokushima university in 2014.
We develop, research and manufacture immune activating food products “MAF Series (Capsule, Spray, Candy, Powder)”, ultrasonic sensitizers and electric field therapy (TTF, ECCT) etc.
Our online store offers our Immune activating food products “MAF series” to domestic and overseas customers.
We are now located in Osaka, and our products are produced in a GMP certified factory in Moriguchi, Osaka.
As a Saisei Mira Group, we cooperate with each clinic and will continue our research and development aiming to treat many diseases such as acute infection, chronic infection, cancer, autism, chronic fatigue syndrome, multiple sclerosis, rheumatoid arthritis, Alzheimer’s disease, dementia and so on.
Saisei Movies
Phase 2 Clinical Trial: Evaluating the Efficacy and Safety of MAF Triple for Aging and Longevity
COVID-19: Clinical Trial Results using MAF Triple (Colostrum MAF and Whey MAF) in Ukraine.
Tumor Treating Field (Electric field) therapy: local cancer destruction and immunotherapy.
COVID-19: Clinical Trial, MAF and Integrative Approaches to Treatment
New video on YouTube is available: Saisei Medical conference 2023
Dr. Toshio Inui
CEO of Saisei Mirai Group
“Rejuvenation and a New Challenge in Infectious Diseases Clinical Trials Using Superfood MAF for COVID-19 in Ukraine Clinical Trials for Telomere Extension in Japan..”
Dr. Antonio Jimenez
Founder and Chief Medical officer Hope4Cancer treatment centers
“The connection between the immune system, Aging, and cancer”
Contact Us
Get in touch
2nd floor, Nature 21 Building
3-34-8 Okubocho
Moriguchi, Osaka 570-0012
Japan
Tel : (+81) 06-6902-1001
Monday – Friday
9:00 AM – 5:00 PM
Coming soon!
Opening of clinic in Lithuania!
For additional information, please contact us or refer to the Saisei Lithuania website below.
Opening of clinic in Lithuania!
For additional information, please contact us or refer to the Saisei Lithuania website below.
We are pleased to announce the opening of our clinic in Serbia.
For additional information and inquiries, please feel free to contact us using the details below.
You are invited to a Zoom webinar.
When: Oct 22, 2023 10:00 AM Osaka, Sapporo, Tokyo
Topic: Saisei Medical Conference 2023 -Advances in Immunotherapy and Rejuvenation: Enhancing Health and Longevity
Register in advance for this webinar:
https://us06web.zoom.us/…/reg…/WN_YJIRkF2cSA6iPZb7b4HCwg
After registering, you will receive a confirmation email containing information about joining the webinar.
read more
CLINICAL STUDY MAF capsules efficacy in post-COVID syndrome treatment is started in KAZAKHSTAN
MedInc Ltd in Kazakhstan on the base of National Research Cardiac Surgery Center has started the implementation of prospective randomized open-label clinical trial: “Evaluation of immune modulator MAF capsules efficacy in a therapy of patients with post-COVID syndrome”. The study sponsored by the developer and manufacturer of the study product Saisei Pharma Co. Ltd, Japan.
The goal of the study is the evaluation of the safety and efficiency of a MAF capsules dietary supplement with anti-inflammatory immune response modulating function in combined treatment of the post-COVID syndrome. |
The trial started in February 2021 and targeted 200 patients with post-COVID syndrome, which will be randomized 1:1 in two groups:
Group 1: SOC (standard of care) + dietary supplement MAF capsules administration for 30 days.
Group 2: SOC
The study primary endpoints aim to evaluate the improvement within 30 days period after MAF capsules administration, where the clinical efficacy refers to an improvement of life quality according to Chalder Fatigue Scale and the “Postcovid syndrome” consequences and symptoms severity evaluation according to ISARIC questionnaire.
The study secondary endpoints included the evaluation of changes according to the Karnofsky Performance Scale and Numerical Rating Scale, and evaluation of the MAF capsules side effects.
The exploratory endpoints include effects on:
1. Lymphocyte count, T cells and its subpopulation count, and B cells count
2. The plasma level of IgG against SARS-CoV-2
read more
- Control group
- MAF Capsules (colostrum MAF) group
- M Capsules (whey MAF) group
- SOC (standard of care)
- SOC plus MAF Capsules (148 mg, 3 caps. TID for 14 days)
- SOC plus M Capsules (148 mg, 3 caps. TID for 14 days)
- No adverse events
- Decrease in the mortality rate
- Decrease in necessity and duration of supplemental oxygen
- Decrease in time to recovery
- Decrease in time until hospital discharge
- Preventing of respiratory failure
- Restoring the base-line decreased lymphocytes count
3rd Generation GcMAF was developed by Saisei Pharma for which we hold patents. There are fake GcMAF products sold online in Australia by a company which is registered in Hong Kong. Please be aware that 3rd Generation GcMAF products are only produced by Saisei Pharma. Any other products from other companies are fake products.
News
We successfully concluded the medical conference! A big thank you to all the doctors who presented.
https://saisei-pharma.co.jp/maf-capsulestriple-en/
The hypothesis: Based on the aforementioned findings and on documented analogies between SARS-CoV-2 and HIV, we hypothesized that the reduced conversion activity of the Gc protein (human group-specific component (Gc)) into the macrophage activating factor (MAF) could have a key role in the dysregulate immune response induced by SARS-CoV-2, just like for HIV infected patients. If this hypothesis is correct, it might help to set a valid strategy of immunotherapy also based on an off-label use of GcMAF in critically ill COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513798/
Conclusion: According to the provided literature overview, we firmly believe that GcMAF deserves be tested as immune-therapeutic to increase macrophages functionality for earlier SARS-CoV-2 viral control, protection against COVID-19 progression by limiting epithelial damage, control local inflammation and prevent from the hyperinflammatory immune response. For this purpose, we planned a Phase-II interventional clinical trial evaluating the effectiveness and safety of Oral immunotherapy with Third Generation GcMAF in hospitalized patients with COVID-19 pneumonia (COral-MAF1 Trial) at the “Ospedale del Mare” Hospital, Naples, Italy.
Saisei Pharma plans clinical study of oral MAF in COVID-19 patients details were featured on some website.
Please check the below URL.
This time, the Saisei Mirai, has contracted official partnership with the Ukrainian National Cancer Center as partner hospitals.
Third
Generation GcMAF
Saisei Mirai
Saisei Pharma
Tokushima University
Developed by Saisei Mirai and Tokushima University in 2014.
MAF Series
• New patents pending production process
• Permitted as a food product in Japan
Second
Generation GcMAF
Developed by Saisei Mirai and the University of Tokushima in 2010.
・High concentration (1500 ng/0.5 ml, 1 dose)
・Significantly higher stability and macrophage activating activity
・Sterilization process using 0.22 μm filtration system
・New patented production process
First
Generation GcMAF
Tokushima University
Dr.Yamamoto
・Low stability at room temperature
・Chemically isolated (purified), sterilization process using 0.22 μm filtration system
・25-(OH) Vitamin D3 Affinity Column
・Affinity column has cross-contamination risk when used repeatedly; must be disposable
Cancer treatments / Skin rejuvenation treatments
Cancer treatments / Immunotherapy
Cancer treatments
Skin Beauty treatments
Saisei Mirai immunotherapy laboratory for the production of GcMAF,
Hyper T/NK cells, lymphocytes and other immunotherapies.
This site is for our patients and medical personnel.
Saisei Pharma is a bio venture company, developing Oral Colostrum GcMAF and researching ultrasonic sensitizers and electric field therapy.
